Blue Skies for Taiwan Act of 2026

S.4259 was introduced on March 26, 2026, by Senator Merkley (D-OR) with three cosponsors (Cruz and Curtis) and referred to the Senate Committee on Foreign Relations. The bill's current status is 'Referred to committee' — it has not been passed, amended, or marked up. The legislation is purely a policy statement: it finds that Taiwan faces gray-zone UAS pressure from China and urges the U.S. to support secure, non-PRC-sourced drone production. However, the bill text contains no authorized appropriation — Section 1 through Section 3 set definitions and findings but include no dollar amounts, no procurement directives, and no contract authority. This means no money is committed, and any eventual funding would require a separate appropriations bill.

The money trail is nonexistent at this stage. Authorization bills like this one set policy ceilings, not actual spending. For any defense contractor to see revenue, the bill must first pass committee, pass the full Senate, pass the House, be signed into law, and then a subsequent appropriations bill must allocate funds specifically for Taiwan UAS procurement. That process typically takes 12-24 months even for high-priority items. The bill explicitly names the 'Blue UAS' program (Defense Contract Management Agency's cleared list), which includes systems from Kratos (KTOS) and AeroVironment (AVAV) as pure-play candidates. Large primes LMT, NOC, and RTX have minor UAS exposure relative to their total revenue, making the structural upside marginal for them.

Looking at real market data, KTOS closed at $61.82 on April 30, 2026, down 12.32% over the past 30 days and near the lower end of its 52-week range ($32.85–$134). AVAV closed at $185.79, up 1.5% over the past 30 days but down 5.34% over the past 7 days. Both stocks have been trending down or flat in April, suggesting no market anticipation of near-term legislative catalysts. The 30-day decline in KTOS (-12.32%) and AVAV's relatively flat performance (+1.5%) indicate that the bill's introduction in late March had no measurable price impact — consistent with the fact that it authorizes zero dollars.

The timeline for any material impact is long. Next steps include potential markups in the Senate Foreign Relations Committee, passage by the full Senate, introduction in the House, conference committee, and eventual appropriations. Given the 119th Congress runs through January 2027, there is a moderate chance this bill could advance to authorization in 2026–2027, but actual procurement funding is at least 12–18 months away even under an accelerated timeline.